

# UROLOGY

## Today

Fall 2004

## A MESSAGE FROM THE CHIEF



Judd W. Moul, MD, FACS  
Professor and Chief

It gives me great pleasure to welcome you to this issue of *Duke Urology Today* as the new Professor and Chief of Urology. I feel extremely honored and blessed to have been given this opportunity. To have had the pleasure to serve in the Army Medical Department for the past 26 years and now have this new leadership role in academic medicine at one of the premier centers in the

World is exciting yet humbling.

Let me speak about humbling first. As only the fourth Chief of Urology since the founding of Duke University School of Medicine in 1930, I am following in the footsteps of some of Urology's greats! While I did not know Dr. Alyea or Dees, I studied their names and legacy in my training. Dr. James Glenn was a "urologic household name" in my residency days because of his well-known textbook. (We all had a real treat when on September 22, Dr Glenn returned to campus to give Urology Grand Rounds on the history of Duke Urology.) Dr. David Paulson was one of "the" prostate cancer "gurus" of the last 20 years who I had the pleasure to work with for a year in the late 80's as a fellow. Last year when Dr. Paulson stepped down, Dr Craig Donatucci stepped in as interim chief and did a spectacular job showing the true Duke spirit of collegiality and integrity in running the Division. Finally, it is humbling to come to a program that is currently ranked #7 in the *US News* and *World Report* rankings and has some of the leading urologists in their respective subspecialty areas in the World.

Now let me focus on excitement. I am excited to be a part of our efforts to move our Division to new heights. We have the talent and the team spirit to take us to a top 3 program over the next few years. My goals are in the following

areas. First and foremost, keep the focus on why we are here: to better care for our patients with urologic disease. Through the three pillars of academic medicine: teaching, research, and clinical care – keep the focus on the patient. Second, do a better job of integrating care with outcome research and clinical trials. We will specifically focus on leveraging information technology to improve our research infrastructure in databasing and tissue banking. In this light, I would like to welcome Leon Sun, M.D., Ph.D. to our program. Leon and I spent the last five years together at the Department of Defense Center for Prostate Disease Research working to develop our military prostate database and tissue/serum banks. We hope to work together with the immense talent at Duke to develop similar initiatives in Urology. Third, we will be building the DukeProstateCenter in collaboration with the Urology Clinic, the Cancer Center, and the Radiation Oncology and Medical Oncology programs.



(l to r) James F. Glenn, MD, Duke Urology Chief  
from 1963 to 1980, with Dr. Moul

By creating a comprehensive program for men and their families with prostate cancer and disease, we will harness the talents of many to better care for our patients and do a better job of incorporating clinical trials with patient care. Fourth, we will reassess the overall direction in our Division

(Continued on next page)

## A MESSAGE FROM THE CHIEF continued

by conducting strategic planning. In January, we will hold a professionally facilitated meeting to engage the stakeholders and I will report to you more in future issues.


I need to go back to the humbling for a moment before I close. Academic medicine and urology is now more complex than ever. I realize that I cannot even come close to leading this effort alone. I have therefore appointed a number of the senior staff to fill leadership roles in the Division. I have appointed Dr Donatucci as Vice Chief for Practice Management. As I stated before, Craig did an outstanding job as interim chief and brought financial stability back to the program. I have appointed Dr Glenn Preminger as the Vice Chief for Education and Training. Glenn is an internationally recognized urologic educator and is one of the leading authorities on stone disease and has been a real help to me in my initial weeks at Duke. Finally, I have

appointed Dr Johannes Vieweg as the Vice Chief for Research. Johannes has become a World-authority on vaccines and immunotherapy of urologic neoplasms and has built a wonderful research program within the Division. He and I will be working together over the next months before the strategic planning meeting to devise a road map for Duke Urology Research over the next decade.

In closing, I want to thank you in advance for your support. I will do my utmost to serve Duke Urology and help our Team excel.

Until next issue, I remain

Very respectfully,



Judd

## UROLOGY RESIDENCY TRAINING PROGRAM



Glenn M. Preminger, MD  
Program Director

The Duke Urology Residency Program continues to thrive. We welcome our new Chief, Judd Moul, MD and his vision of putting the Housestaff first. Although we continue to live under increased scrutiny from the ACGME, the Program has met and exceeded all requirements. We received full accreditation after our Urology Residency Review Committee site visit this past Spring.

All three of our graduating Chief Residents are pursuing Fellowship training in Urologic Oncology: Ganesh V. Raj MD, Ph.D. in Urologic Oncology at Sloan Kettering Memorial Hospital, Costas D. Lallas, MD in Endourology/Laparoscopy at the Mayo Clinic, Scottsdale, and Robert W. Santa-Cruz, MD in Minimally Invasive Urologic Oncology at the University of North Carolina, Chapel Hill and Duke.

A number of awards were presented at the Chief Resident's dinner this past June. Alon Z. Weizer, MD received the Pfizer Scholar Award Fellowship, while Academic Achievement Awards were won by Fernando C.

Delvecchio, MD, Costas D. Lallas, MD, and Ari D. Silverstein, MD.

Duke Urology had a strong showing at the 2004 Southeastern Section of the American Urological Association meeting in Aruba, as 18 papers were presented by Duke Residents and Fellows. In addition, Benjamin K. Yang, MD received first place in the SESAUA's Montague Boyd Essay contest for his submission of "Quality of life following radical perineal prostatectomy" and Alon Z. Weizer, MD was the second place recipient of the T. Leon Howard Pyelogram Program award at the SESAUA meeting.

Resident-based research was also on display at the 2004 AUA meeting in San Francisco, as 24 abstracts were presented by Duke Residents and Fellows. In addition, Ganesh V. Raj, MD, Ph.D. and Benjamin K. Yang, MD received travel scholarships to the Urology Residents and Fellows Forum at the AUA.

Case report honors presented at the 4th Annual NC Residents Seminar held at the Grandover Resort in Greensboro, NC on September 11th went to Regina D. Norris, MD (1st place) and Charles W. Yowell, MD (3rd place).

We greatly appreciate your continued support of the Duke Urology Residency Program.

*(Continued on next page)*

## 2004 Duke Urology Graduates



(l to r) Costas D. Lallas, MD, Robert W. Santa-Cruz, MD, Ganesb V. Raj, MD, PhD

## Alon Z. Weizer, MD - Pfizer Scholar Award Recipient



(l to r) Judd W. Moul, MD, Pfizer representatives Laura Stuart and Naret Viravong, Dr. Weizer, and Glenn M. Preminger, MD

## MEET THE FELLOWS.....

W. Patrick Springhart, MD completed his medical school training at Wright State University in Dayton, Ohio followed by a residency at the University of Illinois in



(l to r) W. Patrick Springhart, MD, Neil D. Sherman, MD, and Roger L. Sur MD

Chicago. His areas of interest are in robotically assisted laparoscopic prostatectomy, laparoscopic surgery, endourology, and the metabolic management of nephrolithiasis. In addition, he is involved

in patient outcomes research in robotic prostatectomy, economic modeling for robotics, and endourologic research.

Neil D. Sherman, MD received his medical degree from New York Medical College in Valhalla, and completed his residency at the University of Medicine and Dentistry of New Jersey. His fellowship interests include neuromodulation for urinary incontinence, post-prostatectomy incontinence, and urethral reconstruction.

Roger L. Sur, MD received his medical degree from Eastern Virginia Medical School and then served as Medical Department Head on a naval warship for several years before returning to a residency at the Naval Medical Center in San Diego, California. His interests include laparoscopic urological surgery as well as endourological surgery. Dr. Sur is also involved with the medical and surgical treatment of kidney stones and surgical improvements in robotics and laparoscopy.

## DUKE UROLOGY CLINICAL TRIALS

The Division of Urology has embarked on a new, exciting effort to increase clinical trial opportunities for patients with urologic disease. Although the Division has been involved in a number of clinical trials for a long time, this effort was primarily driven by individual urologic providers and was not generally a group effort. In mid-2004, the Division decided to create a clinical trials unit to enhance the entire team concept of clinical trial participation.

Ms. Jill Smith, an experienced research coordinator, was hired to coordinate this effort. Her responsibilities will be to work with the Urology senior staff and their physician extenders and other team members to organize a clinical trial unit that incorporates all clinicians and all staff members to enhance patient accrual. Ms. Smith will also be working to increase marketing efforts for clinical trials and to speed up the Institutional Review Board approval process.

Bi-monthly staff meetings have also been established to make sure that the Urology Division team members are fully apprised on new trial offerings and needs for completing existing trials. Dr. Dan George, Duke Urology's Medical Oncologist, working in this area, has been instrumental in organizing this meeting effort.

Within the next 12 months a separate clinical trials office within the Division of Urology will be established to serve as a clearinghouse for anyone in the Division, as well as the newly established DukeProstateCenter, that is interested in referring a patient for a clinical trial.

At the present time, anyone who would like more information on participating in a clinical trial within Duke Urology should contact Ms. Jill Smith at (919) 452-3367 or (919) 668-3613. Clinical trial offerings are also being noted on the Duke Urology website at [www.dukeurology.com](http://www.dukeurology.com).

# UROLOGY RESEARCH

## Karl B. Thor, PhD Discovers First Drug Approved in European Union For Stress Urinary Incontinence

On August 13, 2004, Yentreve (duloxetine hydrochloride) was approved for marketing authorization across the European Union (EU) for the treatment of moderate to severe stress urinary incontinence (SUI) in women. The use of duloxetine for the treatment of stress urinary incontinence was discovered by Karl B. Thor, PhD, Research Associate Professor in the Division of Urology, Dept. of Surgery, DUMC, while he was an employee of Eli Lilly and Co.

Duloxetine is a dual reuptake inhibitor of the neurotransmitters serotonin and norepinephrine. Dr. Thor discovered that by blocking the reuptake of serotonin and norepinephrine in the spinal cord, there is an increase in these neurotransmitters that stimulates activity of the pudendal nerve, which controls the external urethral sphincter. This stimulation is believed to increase contraction of the external urethral sphincter, thereby helping prevent accidental urine leakage with physical activity.

In clinical trials, duloxetine was associated with significant and dose-dependent decreases in frequency of incontinence episodes, correlated with improvements on the Patient Global Impression of Improvement scale and the Incontinence Quality of Life questionnaire. Median

decrease in frequency of incontinence episodes was 41% for placebo, 54% for duloxetine 20 mg daily ( $P=.06$ ), 59% for duloxetine 40 mg daily ( $P=.002$ ), and 64% for duloxetine 80 mg daily ( $P<.001$ ).

Of subjects taking 80 mg per day, half had at least a 64% reduction in incontinence episode frequency ( $P<.001$ ) and 67% had at least a 50% reduction compared with placebo ( $P=.001$ ).

In a subgroup of 163 subjects with more severe stress urinary incontinence who had at least 14 episodes per week, reduction in incontinence episode frequency in the duloxetine groups was 49% to 64%, compared with 30% in the placebo group.

Discontinuation rates for adverse events, most commonly nausea, were 5% for placebo, 9% for duloxetine 20 mg daily, 12% for 40 mg daily, and 15% for 80 mg daily ( $P=.04$ ).

Duloxetine has received an approvable letter from the US FDA and is expected to be approved for use in the US in the first half of next year.

Dr. Thor, along with Dr. Paul Dolber in the Laboratory of NeuroUrology, continue their research to find new therapeutic treatments for lower urinary tract dysfunctions.

## Wendy Demark-Wahnefried, PhD, RD Heads New National Cancer Institute Sponsored Diet and Exercise Trial



A multidisciplinary team of investigators headed by Wendy Demark-Wahnefried, PhD, RD recently was awarded \$2.2 M in funding by the National Cancer Institute to test the impact of a distance medicine-based diet and exercise program on improving physical functioning among cancer survivors who are at least 65 years of age and long term survivors of colorectal, breast or prostate cancer. The rationale behind the RENEW Study: Reach-out to ENhancE Wellness is based upon national statistics which show that 62% of those diagnosed with cancer are surviving at least 5 years beyond diagnosis - numbers that are steadily rising. Yet, a large proportion of cancer survivors are left with significant morbidity, either from the cancer or its treatment, and are at increased risk for secondary cancers, diabetes, osteoporosis and cardiovascular disease. These conditions often lead to decreased physical function and ultimately threaten ability to live independently, especially among those who are older than 65 years of age (the largest proportion of cancer survivors). Thus, there is large public health potential for

interventions that stabilize or positively reorient the functional decline trajectory.

The proposed study builds upon the preliminary work of Demark-Wahnefried, as well as members of her multidisciplinary team, i.e., Elizabeth Clipp, PhD, RN, Miriam Morey, PhD, Harvey Cohen, MD, Carl Pieper, PhD, Denise Snyder, MS and Richard Sloane, MS. which shows that functional decline may be attenuated through such intervention. In January 2005, the team will begin to recruit a total of 640 survivors throughout North America to test the year-long, home-based, telephone-counseling and mailed material intervention aimed at promoting exercise and a healthful portion-controlled diet (<10% of calories from saturated fat, > 5 servings/day of vegetables and fruit). Results of this study will increase our knowledge of the use of distance-medicine to deliver multiple risk factor interventions among older cancer survivors - an ever expanding population in which historically little research has been conducted.

For more information, contact Denise Snyder at (919) 812- 6169.

# American Urological Association Meeting May 8-13, 2004 San Francisco, California


*A Pictorial Perspective by Phillip Dahm, MD*




*The Moscone Center*



*Standing (l to r): Ari Silverstein, MD, Patrick Springhart, MD, Glenn Preminger, MD, Michaela Maloney, Jeremy Wiygul, MD, and Jeffrey Sung. Seated (l to r): Alon Weizer, MD, Charles Marguet, MD.*



*Benjamin K. Yang, MD*



*Glenn M. Preminger, MD*

# FUTURE CONFERENCES:

12/7/04 Duke Tuesday in Urology  
1:00-6:00 pm Searle Conference Center

1/29/05 Winter Urologic Forum  
thru 2/5/05

3/15/05 Duke Urologic Assembly  
thru 3/20/05

Guest Lecturer:  
Laurence A. Levine, MD, FACS  
University Medical Center  
Chicago, Illinois  
Wyndham Peaks Resort  
Telluride, Colorado  
Curacao Marriott Resort  
Piscadera Bay  
Curacao, Netherlands Antilles

For more information, please call us at (919) 684-2033  
or visit our website at [www.dukeurology.com](http://www.dukeurology.com).

## Kudo's .....

Danny O. Jacobs, MD, Professor and Chairman of the Department of Surgery, announced the appointment of **Craig F. Donatucci, MD**, Associate Professor of Urology as Vice Chair for Patient Services. In this role, Dr. Donatucci will develop and implement new clinical policies and procedures for delivery of outpatient surgical services exclusive of operating rooms, working closely with division chiefs, senior staff members of the Private Diagnostic Clinic, as well as other key departmental leaders. His duties will include advising the chair of Surgery on all major components of ambulatory health care delivery systems including practice efficiency, resource utilization, and process management. Dr. Donatucci's initial focus will be establishing productivity measurements and standards and consolidating redundant processes to maximize efficiency while more effectively managing costs and preserving maximal functionality.

**Philipp Dahm, MD**, Assistant Professor of Urology and **Brian C. Murphy, MD**, Assistant Professor of Urology were inducted as founding members of the newly formed "Society for Male Perineal Surgery" at the annual meeting of the American Urological Association held in San Francisco on May 11, 2004. Spearheaded by Dr. Raju Thomas of Tulane University Health Sciences Center, the Society will focus on advancing the cause of male perineal surgical techniques.



*The Society for Male Perineal Surgery*

**Johannes Vieweg, MD**, Associate Professor of Urology and Assistant Professor of Immunology was awarded 550K from the Department of Defense to investigate a cancer vaccine for metastatic prostate cancer.

**Craig F. Donatucci, MD**, Associate Professor of Urology, **Glenn M. Preminger, MD**, Professor of Urology, and **George D. Webster, MB, FRCS**, Professor of Urology, were named North Carolina's Best Doctors in *Business North Carolina's* annual list of North Carolina's Best Doctors, published in the July 2004 edition of *Business North Carolina* magazine.

**Judd W. Moul, MD, FACS**, Professor and Chief of Urology, was listed in "America's Top Doctors 2004" from Castle Connolly Medical Ltd., commonly referred to as the "Castle Connolly Guide" for the second year in a row. Also, upon retirement from the Army in July 2004, the basic science chair at the Department of Defense Center for Prostate Disease Research (CPDR) at the Uniformed Services University of the Health Sciences (USUHS) was named in Dr. Moul's honor.

**George D. Webster, MB, FRCS**, Professor of Urology, was awarded the St. Pauls medal for international contributions to Urology by the British Association of Urologic Surgeons.

Dr. Webster also received the Zimskind Award for lifetime achievements and contributions to Urology by the Society of Urodynamics and Female Urology.

**Thomas J. Polascik, MD, FACS**, Associate Professor of Urology, was elected to the North Carolina Medical Society leadership college.

Dr. Polascik also established Duke as a regional center for cryosurgery training by hosting the first renal and prostate cryotherapy course.

**Joan Guilianelli** was awarded the Southeast Member of the Year Award at the Society of Urologic Nurses and Associates (SUNA) annual conference held in Orlando, Florida, October 22-26, 2004.

# New Faculty

## **Leon Sun, MD, PhD** **Associate Research Professor**

Dr. Sun received his medical degree from Norman Bethune Medical University in 1983, followed by a Masters degree in Pathophysiology from the Third Medical University in 1986 and a Doctoral degree from the Research Institute of Surgery in 1991. After an internship at the First People's Hospital in 1983, he completed residency and fellowship training in cardiovascular surgery at Shenyang General Hospital.

Dr. Sun has served as principal investigator or co-investigator on several funded research projects related to internet-accessible prediction models for the diagnosis, treatment, and follow-up of prostate cancer.

He has received numerous awards and honors such as the "Extraordinary Doctorate of China" award conferred by the National Council, Peoples Republic of China. Dr. Sun has been an invited guest lecturer at universities and national symposiums, and has published more than 50 peer-reviewed articles.

For the past five years, he has served as Research Associate Professor/Database Director at the Centers for Prostate Disease Research at the Uniformed Services University of Health Sciences in Bethesda, Maryland, where he designed, developed, implemented, and managed a nationwide database to record the complete clinical course of prostate cancer.

---

## **CURED: An Opportunity for Everyone to be on the Duke Urology Team**

The Committee for Urologic Research, Education, and Development program is a long-established initiative that allows individuals, corporations, or trusts to provide funding support through gifts and endowments for Duke Urology's research and clinical care programs.

Once a year, we host a meeting and symposium to provide feedback to the CURED members as to how their generous support is helping the Division advance the care we provide to men and women with urologic diseases. This year's meeting was held on November 12 - 13 at the Washington Duke Inn and featured lectures and updates by Duke Urology senior faculty.

Next year's CURED event is scheduled for October 28 - 29, 2005 at the Washington Duke Inn. For more information on how to join the CURED program or for more information on next year's meeting, please contact Ms. Linda Mace at (919) 684-6106.

## **Warren M. Grill, PhD** **Associate Professor of Biomedical Engineering** **Associate Professor of Urology**

Dr. Grill earned his Ph.D. at Case Western Reserve University, where he was most recently Associate Professor of Biomedical Engineering. He has been nominated for both undergraduate and graduate teaching awards, and was awarded the 2002 Excellence in Neural Engineering award by the IEEE-EMBS/BMES. In addition, he received the 2003 Neurotechnology Researcher of the Year award from Neurotech Business Report. Dr. Grill serves on the editorial boards of IEEE Transactions on Neural Systems and Rehabilitation Engineering and Neuromodulation and is a consultant to the Neurological Devices Panel of the Medical Devices Advisory Committee, U.S. Food and Drug Administration. He is one of the nation's leading experts in neural stimulation and neural prostheses.

### **Duke Prostate Cancer Support Group**

For men with prostate cancer and their families, the Duke Cancer Patient Support Program and the Division of Urology offers a support, counseling, and educational program that meets once a month from 7:30 - 9:00 pm in the Morris Building, Conference Room #1993. Many of these meetings include speakers who provide information about various aspects of the disease. They also provide an opportunity to meet other men and their families who are coping with prostate cancer.

For more information, please call the Duke Cancer Patient Support office at (919) 684-4497 or e-mail them at [cancersupport@mc.duke.edu](mailto:cancersupport@mc.duke.edu).

### **ATTENTION DYSURIA MEMBERS SAVE THE DATE**

#### **Retirement Celebration For David F. Paulson, MD**

February 25, 2005 • 4:00 - 6:30 pm  
Searle Conference Center, Duke University Medical Center  
Durham, North Carolina

7:00 pm  
Social at the home of Dr. E. Everett Anderson

February 26, 2005 • 9:00 am - 12:00 noon  
Brunch, Washington-Duke Inn

7:00 - 9:30 pm • Hope Valley Country Club  
Durham, North Carolina



# DUKE UNIVERSITY MEDICAL CENTER

Division of Urology

DUMC 3707 • Durham, NC 27710

ph: 919-684-2033

fax: 919-684-4611

www.dukeurology.com

Non-Profit Org.  
U.S. Postage  
PAID  
Durham, NC  
Permit No. 60

## DIVISION OF UROLOGY CLINICAL FACULTY

**Judd W. Moul, M.D., FACS**  
Professor and Chief of Urology  
Specialty: Urologic Oncology

**David M. Albala, M.D., FACS**  
Professor of Urology  
Specialty: Minimally Invasive Surgery

**Cindy L. Amundsen, M.D.**  
Associate Professor of Obstetrics &  
Gynecology  
Assistant Clinical Professor in Urology  
Specialty: Urogynecology

**Philipp Dahm, M.D.**  
Assistant Professor of Urology  
Specialty: Urologic Oncology &  
Immunotherapy

**Craig F. Donatucci, M.D.**  
Associate Professor of Urology  
Specialty: Male Infertility & Sexual  
Dysfunction

**Daniel J. George, M.D.**  
Associate Professor of Medicine  
Associate Professor of Urology  
Specialty: Medical & Surgical Oncology

**Thomas J. Polascik, M.D., FACS**  
Associate Professor of Urology  
Specialty: Urologic Oncology &  
Minimally Invasive Surgery

**Glenn M. Preminger, M.D.**  
Professor of Urology  
Specialty: Nephrolithiasis & Minimally  
Invasive  
Management of UPJ Obstruction

**Cary N. Robertson, M.D.**  
Associate Professor of Urology  
Specialty: Urologic Oncology

**Johannes Vieweg, M.D., FACS**  
Associate Professor of Urology  
Assistant Professor of Immunology  
Specialty: Urologic Oncology &  
Immunotherapy

**Philip J. Walther, M.D., Ph.D., FACS**  
Professor of Urology  
Associate Professor of Pathology  
Specialty: Urologic Oncology

**George D. Webster, M.B., FRCS**  
Professor of Urology  
Specialty: Reconstructive & Female  
Urology, Urodynamics

Duke Urology Today is published by the Division of Urology at Duke University Medical Center. Comments and inquiries are welcome and should be sent to:

Joan McAlexander, Editor  
DUMC 3707  
Durham, North Carolina 27710  
joan.mcalexander@duke.edu

*Special thanks to Dr. Philipp Dahm  
for providing all the photographs for this newsletter.*